Press Releases

Pharmapack Europe Award Winners 2018

Pharmapack Europe (#PharmapackEU), organised by UBM, announced the winners of the much celebrated 2018 Pharmapack Awards. Due to the outstanding quality of entries, six worthy winners were chosen across two categories, ‘Exhibitor Innovation’ and ‘Health Products’. ...

Vetter introduces South Korea’s pharma and biotech community to meet company management

In an event at its new branch office attended by key customers and business associates, Vetter’s senior management representatives presented the company’s service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. ...

Cobra Biologics and Symbiosis awarded £1.9m ($2.5m USD) Innovate UK Grant

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, announced that they have been awarded a 16-month collaborative...

UPM Raflatac’s insightful pharmaceutical and healtcare labeling at Pharmapack 2018

UPM Raflatac's pharmaceutical and healthcare labeling experts will be present at Pharmapack exhibition on 7-8 February 2018 in Paris, France. Visitors on stand B18 will have the opportunity to see and discuss labeling solutions specified for...

Lonza to Present Latest Research into More Physiologically Relevant ADME-Tox Models at the Society of Toxicology Meeting

During the Society of Toxicology Meeting from 11-15 March 2018 at the Henry B. González Convention Center in San Antonio, TX (USA), Lonza will present two posters highlighting its latest research into developing more physiologically relevant in vitro cell-culture...

Elsevier Welcomes Six Biotech and Pharma Start-ups to The Hive, Supporting the Most Cutting-edge Research in Industry

Elsevier, the global information analytics business specializing in science and health,announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier's innovation initiative for biotech and pharmaceutical start-ups. Exscientia,...

FDA approves Treatment: Lutathera® Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US FDA approval of its NDA for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read